Bvf Inc T Scan Therapeutics, Inc. Transaction History
Bvf Inc
- $3.15 Billion
- Q3 2024
A detailed history of Bvf Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Bvf Inc holds 2,989,474 shares of TCRX stock, worth $9.95 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
2,989,474
Previous 2,989,474
-0.0%
Holding current value
$9.95 Million
Previous $17.5 Million
14.87%
% of portfolio
0.47%
Previous 0.53%
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$17.4 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$16.7 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$14.9 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$14.7 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$9.27 Million0.15% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $63M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...